OBJECTIVE: To examine the feasibility and test-retest reliability of encoding-task functional magnetic resonance imaging (fMRI) in mild Alzheimer disease (AD). DESIGN: Randomized, double-blind, placebo-controlled study. SETTING: Memory clinical trials unit. PARTICIPANTS: We studied 12 patients with mild AD (mean [SEM] Mini-Mental State Examination score, 24.0 [0.7]; mean Clinical Dementia Rating score, 1.0) who had been takingdonepezil hydrochloridefor more than 6 months from the placebo arm of a larger 24-week study (n = 24, 4 scans on weeks 0, 6, 12, and 24, respectively). INTERVENTIONS:Placebo and 3 face-name, paired-associate encoding, block-design blood oxygenation level-dependent fMRI scans in 12 weeks. MAIN OUTCOME MEASURES: We performed whole-brain t maps (P < .001, 5 contiguous voxels) and hippocampal regions-of-interest analyses of extent (percentage of active voxels) and magnitude (percentage of signal change) for novel-greater-than-repeated face-name contrasts. We also calculated intraclass correlation coefficients and power estimates for hippocampal regions of interest. RESULTS:Task tolerability and data yield were high (95 of 96 scans yielded favorable-quality data). Whole-brain maps were stable. Right and left hippocampal regions-of-interest intraclass correlation coefficients were 0.59 to 0.87 and 0.67 to 0.74, respectively. To detect 25.0% to 50.0% changes in week-0 to week-12 hippocampal activity using left-right extent or right magnitude with 80.0% power (2-sided α = .05) requires 14 to 51 patients. Using left magnitude requires 125 patients because of relatively small signal to variance ratios. CONCLUSIONS: Encoding-task fMRI was successfully implemented in a single-site, 24-week, AD randomized controlled trial. Week 0 to 12 whole-brain t maps were stable, and test-retest reliability of hippocampal fMRI measures ranged from moderate to substantial. Right hippocampal magnitude may be the most promising of these candidate measures in a leveraged context. These initial estimates of test-retest reliability and power justify evaluation of encoding-task fMRI as a potential biomarker for signal of effect in exploratory and proof-of-concept trials in mild AD. Validation of these results with larger sample sizes and assessment in multisite studies is warranted.
RCT Entities:
OBJECTIVE: To examine the feasibility and test-retest reliability of encoding-task functional magnetic resonance imaging (fMRI) in mild Alzheimer disease (AD). DESIGN: Randomized, double-blind, placebo-controlled study. SETTING: Memory clinical trials unit. PARTICIPANTS: We studied 12 patients with mild AD (mean [SEM] Mini-Mental State Examination score, 24.0 [0.7]; mean Clinical Dementia Rating score, 1.0) who had been taking donepezil hydrochloride for more than 6 months from the placebo arm of a larger 24-week study (n = 24, 4 scans on weeks 0, 6, 12, and 24, respectively). INTERVENTIONS: Placebo and 3 face-name, paired-associate encoding, block-design blood oxygenation level-dependent fMRI scans in 12 weeks. MAIN OUTCOME MEASURES: We performed whole-brain t maps (P < .001, 5 contiguous voxels) and hippocampal regions-of-interest analyses of extent (percentage of active voxels) and magnitude (percentage of signal change) for novel-greater-than-repeated face-name contrasts. We also calculated intraclass correlation coefficients and power estimates for hippocampal regions of interest. RESULTS: Task tolerability and data yield were high (95 of 96 scans yielded favorable-quality data). Whole-brain maps were stable. Right and left hippocampal regions-of-interest intraclass correlation coefficients were 0.59 to 0.87 and 0.67 to 0.74, respectively. To detect 25.0% to 50.0% changes in week-0 to week-12 hippocampal activity using left-right extent or right magnitude with 80.0% power (2-sided α = .05) requires 14 to 51 patients. Using left magnitude requires 125 patients because of relatively small signal to variance ratios. CONCLUSIONS: Encoding-task fMRI was successfully implemented in a single-site, 24-week, AD randomized controlled trial. Week 0 to 12 whole-brain t maps were stable, and test-retest reliability of hippocampal fMRI measures ranged from moderate to substantial. Right hippocampal magnitude may be the most promising of these candidate measures in a leveraged context. These initial estimates of test-retest reliability and power justify evaluation of encoding-task fMRI as a potential biomarker for signal of effect in exploratory and proof-of-concept trials in mild AD. Validation of these results with larger sample sizes and assessment in multisite studies is warranted.
Authors: Clifford R Jack; Matt A Bernstein; Bret J Borowski; Jeffrey L Gunter; Nick C Fox; Paul M Thompson; Norbert Schuff; Gunnar Krueger; Ronald J Killiany; Charles S Decarli; Anders M Dale; Owen W Carmichael; Duygu Tosun; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: Alexandra Golby; Gerald Silverberg; Elizabeth Race; Susan Gabrieli; James O'Shea; Kyle Knierim; Glenn Stebbins; John Gabrieli Journal: Brain Date: 2005-02-10 Impact factor: 13.501
Authors: Kim A Celone; Vince D Calhoun; Bradford C Dickerson; Alireza Atri; Elizabeth F Chua; Saul L Miller; Kristina DePeau; Doreen M Rentz; Dennis J Selkoe; Deborah Blacker; Marilyn S Albert; Reisa A Sperling Journal: J Neurosci Date: 2006-10-04 Impact factor: 6.167
Authors: Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel Journal: JAMA Date: 2004-01-21 Impact factor: 56.272
Authors: Donald G McLaren; Aishwarya Sreenivasan; Eli L Diamond; Meghan B Mitchell; Koene R A Van Dijk; Amy N Deluca; Jacqueline L O'Brien; Dorene M Rentz; Reisa A Sperling; Alireza Atri Journal: Neurodegener Dis Date: 2012-03-27 Impact factor: 2.977
Authors: Kaiming Li; Lei Guo; Carlos Faraco; Dajiang Zhu; Hanbo Chen; Yixuan Yuan; Jinglei Lv; Fan Deng; Xi Jiang; Tuo Zhang; Xintao Hu; Degang Zhang; L Stephen Miller; Tianming Liu Journal: Neuroimage Date: 2012-03-05 Impact factor: 6.556
Authors: Axel Montagne; Daniel A Nation; Judy Pa; Melanie D Sweeney; Arthur W Toga; Berislav V Zlokovic Journal: Acta Neuropathol Date: 2016-04-01 Impact factor: 17.088
Authors: Lori L Beason-Held; Andrea T Shafer; Joshua O Goh; Bennett A Landman; Christos Davatzikos; Brieana Viscomi; Jessica Ash; Melissa Kitner-Triolo; Luigi Ferrucci; Susan M Resnick Journal: Brain Imaging Behav Date: 2021-04 Impact factor: 3.224
Authors: Haley G Trontel; Tyler C Duffield; Erin D Bigler; Alyson Froehlich; Molly B D Prigge; Jared A Nielsen; Jason R Cooperrider; Annahir N Cariello; Brittany G Travers; Jeffrey S Anderson; Brandon A Zielinski; Andrew Alexander; Nicholas Lange; Janet E Lainhart Journal: Behav Sci (Basel) Date: 2013